New Perspectives in Hemodialysis, Peritoneal Dialysis, Arteriovenous Hemofiltration, and Plasmapheresis

Häftad, Engelska, 2012

AvWalter Hörl,P.J. Schollmeyer,P. J. Schollmeyer,Walter Horl

709 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

Produktinformation

Utgivningsdatum2012-03-19
Mått178 x 254 x undefined mm
FormatHäftad
SpråkEngelska
SerieAdvances in Experimental Medicine and Biology
Antal sidor218
FörlagSpringer-Verlag New York Inc.
ISBN9781468457209

Tillhör följande kategorier

Medicinsk utrustning och medicinska tekniker inom Medicin

I New Perspectives in Hemodialysis.- Protein catabolic factors in patients on renal replacement therapy.- ?2 Microglobulin-derived amyloid in dialysis patients.- Mechanisms and consequences of complement activation during hemodialysis.- Neutrophil activation during hemodialysis.- Biocompatibility — a system approach.- Treatment of uremic anaemia with recombinant human erythropoietin.- Endocrine abnormalities in patients with endstage renal failure.- Carnitine supplementation in uremia.- II Pharmacological Therapy in Dialyzed Patients.- Pathophysiology and treatment of hypertension in dialysis patients.- Adjustment of drug dosage to hemodialysis patients.- Pharmacokinetic aspects of drug transport in continuous ambulatory peritoneal dialysis.- Drug therapy during continuous arteriovenous hemofiltration.- III New Perspectives in Peritoneal Dialysis.- The biology of the peritoneal membrane during chronic peritoneal dialysis.- Lymphatic absorption during peritoneal dialysis.- CAPD with bicarbonate solution.- Glucose polymer as an osmotic agent in CAPD.- Effects of long-term treatment with human recombinant erythropoietin in patients on CAPD.- IV New Perspectives in Hemofiltration and Plasmapheresis.- Continuous arterio-venous hemofiltration: Optimization of technical procedures and new directions.- Is continuous haemofiltration superior to intermittent dialysis and haemofiltration treatment?.- Therapeutic apheresis update.- Treatment combining plasmapheresis and pulse cyclophosphamide in severe systemic lupus erythematosus.